PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32793908-6	2020	In some human cells, remdesivir increases ACE2-promoter luciferase-reporter expression, ACE2 mRNA and protein, and ACE2 expression is attenuated by MEKi.	remdesivir	21-31	angiotensin converting enzyme 2	Homo sapiens	42-46	
33179852-0	2021	Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection.	remdesivir	42-52	angiotensin converting enzyme 2	Homo sapiens	14-18	
33245731-5	2020	In some human cells, remdesivir increases ACE2-promoter luciferase-reporter expression, ACE2 mRNA and protein, and ACE2 expression is attenuated by MEKi.	remdesivir	21-31	angiotensin converting enzyme 2	Homo sapiens	42-46	
33245731-5	2020	In some human cells, remdesivir increases ACE2-promoter luciferase-reporter expression, ACE2 mRNA and protein, and ACE2 expression is attenuated by MEKi.	remdesivir	21-31	angiotensin converting enzyme 2	Homo sapiens	88-92	
33245731-5	2020	In some human cells, remdesivir increases ACE2-promoter luciferase-reporter expression, ACE2 mRNA and protein, and ACE2 expression is attenuated by MEKi.	remdesivir	21-31	angiotensin converting enzyme 2	Homo sapiens	88-92	
33245731-6	2020	In serum-deprived and stimulated cells treated with remdesivir and MEKi we observed correlations between pRB, pERK, and ACE2 expression further supporting role of proliferative state and MAPK pathway in ACE2 regulation.	remdesivir	52-62	angiotensin converting enzyme 2	Homo sapiens	120-124	
33245731-6	2020	In serum-deprived and stimulated cells treated with remdesivir and MEKi we observed correlations between pRB, pERK, and ACE2 expression further supporting role of proliferative state and MAPK pathway in ACE2 regulation.	remdesivir	52-62	angiotensin converting enzyme 2	Homo sapiens	203-207	
32643603-7	2020	Ad5-hACE2-transduced mice enabled rapid assessments of a vaccine candidate, of human convalescent plasma, and of two antiviral therapies (poly I:C and remdesivir).	remdesivir	151-161	angiotensin converting enzyme 2	Homo sapiens	4-9	
32793908-6	2020	In some human cells, remdesivir increases ACE2-promoter luciferase-reporter expression, ACE2 mRNA and protein, and ACE2 expression is attenuated by MEKi.	remdesivir	21-31	angiotensin converting enzyme 2	Homo sapiens	88-92	
32793908-6	2020	In some human cells, remdesivir increases ACE2-promoter luciferase-reporter expression, ACE2 mRNA and protein, and ACE2 expression is attenuated by MEKi.	remdesivir	21-31	angiotensin converting enzyme 2	Homo sapiens	88-92	
32375574-2	2021	This study demonstrated the putative inhibitory potential of lopinavir, remdesivir, oseltamir, azithromycin, ribavirin, and chloroquine towards V-ATPase, protein kinase A, SARS-CoV spike glycoprotein/ACE-2 complex and viral proteases.	remdesivir	72-82	angiotensin converting enzyme 2	Homo sapiens	200-205	
32607511-7	2020	When tested against this reporter virus, remdesivir exhibited substantially more potent activity in A549-hACE2 cells compared to Vero E6 cells (EC 50 0.115 vs 1.28 muM), while this difference was not observed for chloroquine (EC 50 1.32 vs 3.52 muM), underscoring the importance of selecting appropriate cells for antiviral testing.	remdesivir	41-51	angiotensin converting enzyme 2	Homo sapiens	105-110	
34746476-11	2021	Echoside A and echoside B showed higher docking score than remdesivir as COVID-19 drug on four target proteins, i.e., spike protein (-7.9 kcal/mol and -7.8 kcal/mol), RBD-ACE2 (-7.5 kcal/mol and -8.2 kcal/mol), 3CLpro (-8.4 kcal/mol and -9.4 kcal/mol) and RdRp (-7.3 kcal/mol and -8.0 kcal/mol).	remdesivir	59-69	angiotensin converting enzyme 2	Homo sapiens	171-175	
34631362-7	2021	Captopril, moexipril, benazepril, fosinopril, losartan, remdesivir, Sigma ACEI, NAA, and NAM interacted and docked at the interface of ACE2 and SARS-CoV-2 spike protein complex.	remdesivir	56-66	angiotensin converting enzyme 2	Homo sapiens	135-139	
34229582-5	2021	A fourth drug, remdesivir, bound approximately equally to both the ACE2 and viral spike RBD, thus potentially increasing risk of viral infection by bringing the spike protein into closer proximity to the ACE2 receptor.	remdesivir	15-25	angiotensin converting enzyme 2	Homo sapiens	67-71	
34568544-7	2021	Meanwhile, bexarotene and cetilistat bind more tightly to the SARS-CoV-2 main protease and the ACE2 receptor, respectively, than remdesivir, a potential treatment for COVID-19 that is the first FDA-approved drug against this virus.	remdesivir	129-139	angiotensin converting enzyme 2	Homo sapiens	95-99	
35595082-9	2022	Interestingly, the U87.ACE2+ cells could be successfully implemented in an MTS-based colorimetric CPE reduction assay, providing IC50 values for Remdesivir and Nirmatrelvir in the (low) nanomolar range.	remdesivir	145-155	angiotensin converting enzyme 2	Homo sapiens	23-27